Advanced search
Publication Cover
British Journal of Neurosurgery Volume 14, 2000 - Issue 1
Submit an article Journal homepage
117
Views
45
CrossRef citations to date
0
Altmetric
Research Article

Expression of p19 INK4d, CDK4, CDK6 in glioblastoma multiforme

P. Y. P. Lam, E. di Tomaso, H.-K. Ng, J. C. S. Pang, M. F. Roussel, N. M. Hjelm Departments of Anatomical and Cellular Pathology; Chemical Pathology,The Chinese University of Hong Kong Shatin, Hong Kong; Department of Tumour Cell Biology, St Jude Childrens Research Hospital, Memphis,Tennessee 38105, USA
Pages 28-32 | Published online: 06 Jul 2009

  • Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
  • Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
  • Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
  • Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O‘Keefe CL, Matera AG, Xiong Y. Growth suppression by p 18, a p16INK4/MTS1- and p14INK4B/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
  • Hirai H, Roussel MF, Karo JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p 19 and p 18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
  • Chan FKM, Zhang J, Chen L, Shapiro DN, Winto A. Identification of human and mouse p 19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 1995;15:2682-8.
  • Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
  • Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 1996;13:1615-19.
  • Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J. Mutations of the p16 gene in gliomas. Oncogene 1996; 12:63-7.
  • He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7.
  • Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol Biol 1997;94:303-9.
  • Ichimura K, Schmidt EE, Goike HM and Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
  • Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR. Molecular cloning, expression pattern, and chromosomal localization of human CDK2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 1995;29:623-30.
  • Zindy F, Soares H, Herzog KH, Morgan J, Sherr CJ, Roussel MF. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. Cell Growth Differ 1997;8:1139-50.
  • von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumour suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-9.
  • von Deimling A, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994;57:676-80.
  • Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 1995;12:277-82.
  • Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995;11:597-600.
  • Barker FG, Chen P, Furman F, Aldape KD, Edwards MS, Israel MA. p16 deletion and mutation analysis in human brain tumours. J Neurooncol 1997;31:17-23.
  • Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75:2-8.
  • Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDK2Abeta alleles: evidence for an KB-independent growth suppressive pathway. Oncogene 1997;15:2013-20.
  • Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, CDK4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57:122-30.
  • Gemma A, Takenoshita S, Hagiwara K, Okamoto A, Spillare EA, McMemamin MG, Hussain SP, Forrester K, Zariwala M, Xiong Y, Harris CC. Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15[sup INK4b/MTS2], p16[sup INK4a/MTS1], p18 and p 19 in human cancer cell lines. Int J Cancer 1996;68:605-11.
  • Zariwala M, Xiong Y. Lack of mutation in the cyclin-dependent kinase inhibitor, p19[INK4d], in tumourderived cell lines and primary tumours. Oncogene 1996;13:2033-8.
  • Miller CW, Yeon C, Aslo A, Mendoza S, Aytac U, Koeffler HP. The p19[sup INK4d] cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene 1997;15: 231-5.
  • Shiohara M, Spirin K, Said JW, et al. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia 1996;10:1897-900.
  • Latham KM, Eastman SW, Wong A, Hinds PW. Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol Cell Biol 1996;16: 4445-55.
  • Ohgaki H, Schauble B, zur Hausen A, yon Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-18.
  • Rollbrocker B, Waha A, Louis DN, Wiestler OD, yon Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high CDK4 protein levels in glioblastoma multiforme. Acta Neuropathol (Biol) 1996;92:70-4.
  • Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang H-J, Cavenee WK. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-4.
  • Holland EC, Hively WP, Gallo V, Varmus HE. Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Der 1998;12:3644-9.
  • Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Der 1998;12:3675-85.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.